APVO News and Press, Aptevo Therapeutics Inc. From 04/10/24

Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ALG.APV-527 clinical trial Cohort 5 dos...

A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 96.2% to $0.0785 on volume of 428,216,483 shares Mobile Global Esports Inc. (MGAM) rose 77.8% to $0.216 on volume of 139,335,972 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.61 on volume of 128,866...

2024-03-18 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the ...

2024-03-13 13:18:36 ET More on Mid-day movers & stocks. Arq, Inc. (ARQ) Q4 2023 Earnings Call Transcript Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Therape...

2024-03-08 10:00:23 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

2024-03-08 08:40:50 ET Losers: Amylyx Pharmaceuticals ( AMLX ) -81% as late-stage ALS trial for Relyvrio fails . BigBear.ai Holdings BBAI -20% after Q4 earnings release . AerSale Corp ASLE -20% after Q4 earnings release . OppFi OPFI -17% aft...

Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activity Early promising signs of clinical activity in heavily pretreated patients Dose-escalation trial data on track for readout 2H 2024 LUND, SWEDEN and SEATTLE WA / ACCESSWIRE / March 7, 2024 ...

2024-03-06 08:02:02 ET Aptevo Therapeutics Inc (APVO) announced stock split at a ratio of 1-for-44 on 2024-03-06 ... Full story available on KlickAnalytics.com

Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA / A...